External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

ICICI Securities Ltd

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Akums Drugs and Pharmaceuticals / Equity Bottom-Up

Akums Drugs and Pharmaceuticals (0200361D IN)

<ul><li>Akums Drugs and Pharmaceuticals (Akums) in Q3FY25 saw its CDMO business’ volumes recovering (+0.6% YoY).</li><li>Growth in CDMO should pick up in the next few quarters given Akums’ healthy order book alongside API prices also settling.</li><li>EBITDA margins leaped 160bps to 12% as the company curbs losses (down 34% YoY/24% QoQ) in its API business; margins in CDMO were steady at 15.4%.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Akums Drugs and Pharmaceuticals (Akums) in Q3FY25 saw its CDMO business’ volumes recovering (+0.6% YoY).Growth in CDMO should pick up in the next few quarters given Akums’ healthy order book alongside API prices also settling.EBITDA margins leaped 160bps to 12% as the company curbs losses (down 34% YoY/24% QoQ) in its API business; margins in CDMO were steady at 15.4%.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Akums Drugs and Pharmaceuticals - On the Path to Recovery